Oncology News and Research

RSS
New immuno-oncology drug helps body's own immune system to fend off cancer

New immuno-oncology drug helps body's own immune system to fend off cancer

Many patients do not experience dignified death, say physicians in cancer centers

Many patients do not experience dignified death, say physicians in cancer centers

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Study could lead to improvements in outcomes for women with triple-negative breast cancer

Study could lead to improvements in outcomes for women with triple-negative breast cancer

Researchers make important progress in defining new genetic causes of Wilms tumor

Researchers make important progress in defining new genetic causes of Wilms tumor

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Keytruda drug gets FDA approval for treatment of advanced melanoma

Keytruda drug gets FDA approval for treatment of advanced melanoma

Socio-economic barriers preclude patients from receiving breast conserving therapy

Socio-economic barriers preclude patients from receiving breast conserving therapy

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

Scientists identify genetic mutations in endometrioid endometrial carcinoma

Scientists identify genetic mutations in endometrioid endometrial carcinoma

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Research reveals that unplanned births out-of-hospital linked with higher infant mortality

Research reveals that unplanned births out-of-hospital linked with higher infant mortality

Organizations across U.S. participating in Go Gold for Childhood Cancer Awareness campaign

Organizations across U.S. participating in Go Gold for Childhood Cancer Awareness campaign

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

Two fully automated molecular testing systems for blood and plasma donor screening launched by Roche

Two fully automated molecular testing systems for blood and plasma donor screening launched by Roche

Gene therapy may offer significant advantages in prevention of botulism exposure

Gene therapy may offer significant advantages in prevention of botulism exposure

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.